|
|
|
|
이성현 ( Lee Seong-Hyeon ) - Korea University College of Medicine Department of Obstetrics and Gynecology
안기훈 ( Ahn Ki-Hoon ) - Korea University College of Medicine Department of Obstetrics and Gynecology
|
|
Abstract
|
|
|
|
|
|
Several vaccines have been developed to combat the coronavirus disease 2019 (COVID-19), including messenger Ribonucleic acid (mRNA, Pfizer-BioNtech, and Moderna) and viral vector (AstraZeneca and Janssen) types. Unfortunately, reports of COVID-19 exposure during pregnancy are scarce, as pregnancy and breastfeeding were among the exclusion criteria in the efficacy and safety studies of major COVID-19 vaccines. The U.S. Centers for Disease Control and Prevention recently included pregnancy as a risk factor for severe COVID-19 infection, although the absolute risk is low. Previous experience in pregnant women with mRNA vaccines is lacking despite such vaccines not using live viruses, being unable to cause disease, not interacting with an individual's DNA, and being unable to cause genetic mutations. In addition, previous studies in animals have not revealed any safety issues with such vaccine types for female reproduction or fetal development. Vaccine-induced antibody titers were equivalent in pregnant and lactating women versus non-pregnant women. Given the data on increased mortality and morbidity associated with COVID-19 during pregnancy, it may be unethical to withhold vaccinations based on a theoretical risk and a lack of clinical research in this population. Additionally, a careful review of the vaccination recommendations for pregnant women by the academic community and government through additional efficacy and safety studies tailored to the situation in Korea is needed.
|
|
|
KeyWords
|
|
Coronavirus disease 2019, COVID-19 vaccine, Maternal immunity, mRNA vaccine, Severe acute respiratory syndrome coronavirus 2, Vaccine safety
|
|
|
원문 및 링크아웃 정보
|
|
|
|
|
등재저널 정보
|
|
|
|
|
|
|